Citigroup
NVCT icon

Citigroup’s Nuvectis Pharma NVCT Stock Holding History

Citigroup’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$147K Buy
8,015
+7,191
+873% +$80.5K ﹤0.01% 4486
2026
Q1 		$6.37K Buy
824
+438
+113% +$3.75K ﹤0.01% 5192
2025
Q4 		$2.92K Sell
386
-160
-29% -$1.04K ﹤0.01% 5393
2025
Q3 		$3.29K Sell
546
-4,026
-88% -$27.7K ﹤0.01% 5354
2025
Q2 		$34.2K Buy
4,572
+3,547
+346% +$32.2K ﹤0.01% 4934
2025
Q1 		$10K Buy
+1,025
New +$7.38K ﹤0.01% 5200
2024
Q4 		– Sell
-8,887
Closed -$55.9K – 5913
2024
Q3 		$55.9K Buy
8,887
+4,004
+82% +$26.3K ﹤0.01% 4988
2024
Q2 		$30.9K Buy
4,883
+3,501
+253% +$23.8K ﹤0.01% 4850
2024
Q1 		$11.3K Buy
1,382
+274
+25% +$2.33K ﹤0.01% 5173
2023
Q4 		$9.24K Buy
1,108
+1,103
+22,060% +$9.84K ﹤0.01% 5209
2023
Q3 		$65 Sell
5
-2,034
-100% -$29.5K ﹤0.01% 5496
2023
Q2 		$32.6K Buy
+2,039
New +$32.5K ﹤0.01% 4827

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Citigroup's NVCT Position: Q2 2026 in Review

Citigroup increased its Nuvectis Pharma (NVCT) stake by 873% in Q2 2026, buying an estimated $80.5K and bringing the position to 8,015 shares worth $147K. The position accounts for ﹤0.01% of the portfolio, ranked #4486.

Citigroup first reported a position in NVCT in Q2 2023 and has held it in 12 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Citigroup held 8,015 shares of Nuvectis Pharma worth $147K as of Q2 2026.
  • Citigroup bought 7,191 Nuvectis Pharma shares in Q2 2026, an estimated $80.5K.
  • Nuvectis Pharma made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4486 holding.
  • Citigroup first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 12 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.